New data at WCLC may shrink PD-1 lung cancer opportunity. Bristol still leads but Roche’s PD-L1 may
Updated data presented this week at the World Conference on Lung cancer revealed Bristol’s anti PD1 immunotherapy Opdivo failed to...
top of page
Recent Research
Jul 20, 2015
BMY.US: Opdivo positive kidney cancer headline unlikely driven by subgroup as seen in non-squamous l
Bristol-Myers have just announced that their second line kidney cancer study CHECKMATE 025 of Opdivo vs chemo was stopped early, as it...
Jul 13, 2015
ROG.VX: MPDL3280a likely first in bladder, but market worth $100m as pricing already set
Roche's MPDL3280a in bladder cancer is likely to be first anti PD-1/PD-L1 in this setting, but competitors are setting the price and...
Jun 2, 2015
Far from a level playing field in lung post ASCO
Opdivo still leads in lung cancer, though PD1 market continues to shrink from consensus' lofty expectations... Overall this year’s ASCO...
May 29, 2015
BMY.US: Opdivo not better than chemo in 44% of 2nd line lung cancer
Opdivo not better than chemo in 44% of 2nd line lung cancer: non-squamous, PD-L1-ve in CHECKMATE 057 As we suspected in our previous...
May 27, 2015
ASCO Late Breakers to watch
ASCO PD1 Late breakers in Lung, Melanoma, Colon, Liver and Head & Neck With ASCO abstracts already out, the currently embargoed late...
May 19, 2015
ROG.VX: Roche's anti PD-L1 must be restricted in 2nd line lung unlike competitor, without superi
Roche's MPDL worse than chemo in 2nd line PD-L1-ve lung, but doesn't have better data in PDL1 +ves either Much excitement has been caused...
Mar 31, 2015
Honing in on targeted therapy may take the sting out of the PD-1 market
Anti PD-1 commercial potential may be vastly overestimated With PD-1 checkpoint inhibition clearly set to improve the landscape of cancer...
Archive
Search By Tags
Follow Us
Bloomberg: FOVL <go>
ThomsonReuters
FactSet
Captial IQ
bottom of page